服用纳地美定出现过敏怎么办？

Natimide

It is an opioid antagonist indicated for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. The recommended dosage is 0.2 mg, taken once daily with or without food.

Treatment of Nadimedine Allergy

Some patients may develop allergic symptoms when taking naldimedine, the more common ones being bronchospasm and rash, which require targeted treatment based on different allergic symptoms.

1. Bronchospasm

Patients can stop taking the medication promptly as directed by the doctor, and can use β2 receptor agonists, which can alleviate bronchospasm and avoid continued medication.

2. Rash

1. Pay attention to skin care: After a rash occurs, pay attention to keeping the skin clean and hygienic. Avoid using highly irritating or alkaline toiletries when washing. Apply mild lotion after bathing to keep the skin moist and avoid dryness.

2. Avoid scratching the skin: The rash area may be itchy. It is recommended to avoid excessive scratching to avoid skin ulceration, infection, redness, swelling, pain and other symptoms.

3. Pay attention to your diet: avoid spicy and irritating foods, such as chili peppers, spicy hot pot, garlic, etc., to avoid irritating the rash and aggravating it.

4. Pay attention to sun protection: Avoid ultraviolet rays in the rash area, and take sun protection measures when going out, such as applying sunscreen, wearing a sun hat, using an umbrella, etc., to avoid melanin pigmentation in the rash area.

The clinical practice of nadimedine

Naldimedine, as a gastrointestinal opioid receptor antagonist, improves OIC in patients with CNCP and does not interfere with the analgesic properties of opioids or cause withdrawal symptoms because these effects are centrally mediated and naldimedine does not cross the blood-brain barrier. Naldimedine showed significant and sustained improvements in bowel movement frequency, quality of life, and constipation-related symptoms.

Compared with placebo, it was generally well tolerated, with a higher incidence of mild or moderate gastrointestinal adverse events, such as diarrhea, abdominal pain, or vomiting. Naldimedine at 0.2 mg daily significantly improved symptoms in patients with opioid-induced constipation and was well tolerated.

After oral administration, in the fasting state, the time for naldimedine absorption to reach peak concentration (Tmax) is approximately 0.75 hours, the plasma protein binding rate is 93%-94%, and the terminal elimination half-life is 11 hours. High-fat foods reduce the rate but not the extent of naldimedine absorption.

Recommended related articles: